Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Pablo Cueva"'
Autor:
Mar Llamas‐Velasco, Ofelia Baniandrés, Raquel Rivera, Ana Reymundo Jimenez, Mercedes Hospital, Elena García Zamora, Álvaro González‐Cantero, Juan‐José Andrés Lencina, Esteban Daudén, Pablo Cueva
Publikováno v:
Dermatologic Therapy. 33
A change of pricing policy in Spain have made both doses of ustekinumab (UST), 45 and 90 mg, recently available at the same price. Our primary objective was to evaluate effectiveness of UST 90 mg at 52 and 104 weeks in psoriasis patients in clinical
Autor:
Janete Ferreira Andrade, Eduardo Soares Calixto, Guilherme Ramos Demetrio, Henrique Venâncio, Marcos Vinicius Meiado, Denise Garcia de Santana, Pablo Cuevas-Reyes, Wanessa Rejane de Almeida, Jean Carlos Santos
Publikováno v:
Plants, Vol 13, Iss 11, p 1472 (2024)
Variations in plant genotypes and phenotypes are expressed in ways that lead to the development of defensive abilities against herbivory. Induced defenses are mechanisms that affect herbivore insect preferences and performance. We evaluated the perfo
Externí odkaz:
https://doaj.org/article/9bfbb2b9e56a4ecfaaabd2cac9d5d915
Autor:
Hernán A. Navarro, Chunyang Jin, Lawrence E. Brieaddy, Juan Pablo Cueva, Scott P. Runyon, F. Ivy Carroll, Chad M. Kormos, S. Wayne Mascarella, James B. Thomas, Brian P. Gilmour
Publikováno v:
Journal of Medicinal Chemistry. 56:4551-4567
There is continuing interest in the discovery and development of new κ opioid receptor antagonists. We recently reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid receptor antagonists. In this study, we re
Autor:
Benjamin R. Chemel, Markus A. Lill, Val J. Watts, Jose I. Juncosa, David E. Nichols, Juan Pablo Cueva
Publikováno v:
European Journal of Medicinal Chemistry. 48:97-107
Efforts to develop selective agonists for dopamine D(1)-like receptors led to the discovery of dihydrexidine and doxanthrine, two bioisosteric β-phenyldopamine-type full agonist ligands that display selectivity and potency at D(1)-like receptors. We
Autor:
Markus A. Lill, David E. Nichols, Juan Pablo Cueva, Jose I. Juncosa, Val J. Watts, Alejandra Gallardo-Godoy, Pierre A. Vidi
Publikováno v:
Journal of Medicinal Chemistry. 54:5508-5521
To probe the space at the floor of the orthosteric ligand binding site in the dopamine D(1) receptor, four methylated analogues of dihydrexidine (DHX) were synthesized with substitutions at the 7 and 8 positions. The 8α-axial, 8β-equatorial, and 7
Autor:
David E. Nichols, John D. McCorvy, Aubrie A. Harland, Juan Pablo Cueva, Alia H. Clark, Val J. Watts
Publikováno v:
ARKIVOC, Vol 2010, Iss 4, Pp 125-138 (2011)
To assess the importance of conformation and placement of the β-substituent of agonist ligands targeted to the D1 dopamine receptor, (±)-trans-6,6a,7,8,13,13a-hexahydrobenzo[e]chromeno [3,4-b]azepine-2,3-diol 5 and (±)-trans-6,6a,7,8,9,13b-hexahyd
Autor:
Juan Pablo Cueva, Frank I. Carroll, Scott P. Runyon, James B. Thomas, Hernán A. Navarro, S. W. Mascarella
Publikováno v:
ACS Medicinal Chemistry Letters. 1:365-369
This report describes the discovery that 1-substituted 4-(3-hydroxyphenyl)piperazines are pure opioid receptor antagonists. Compounds in this new series include N-phenylpropyl (3S)-3-methyl-4-(3-hydroxyphenyl)piperazine and (3R)-3-methyl-4-(3-hydroxy
Autor:
Juan Pablo Cueva, F. Ivy Carroll, Hernán A. Navarro, Tingwei Bill Cai, James B. Thomas, S. Wayne Mascarella
Publikováno v:
Journal of Medicinal Chemistry. 52:7463-7472
In previous structure−activity relationship (SAR) studies, (3R)-7-hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic, 3) was identified as the first
Autor:
David E. Nichols, Juan Pablo Cueva
Publikováno v:
Synthesis. 2009:715-720
An efficient synthesis of the dopamine D 1 selective full agonist dihydrexidine has been achieved in high yields and requiring no chromatographic separations via a facilitated intramolecular Henry cyclization of a (nitropropyl)benzophenone and subseq
Autor:
Juan Pablo Cueva, Mary J. Clark, John W. Lewis, Vinod Kumar, Stephen M. Husbands, Christopher Roche, John R. Traynor, Todd M. Hillhouse, Mehrnoosh Ostovar
Publikováno v:
Journal of Medicinal Chemistry
Cueva, J P, Roche, C, Ostovar, M, Kumar, V, Clark, M J, Hillhouse, T M, Lewis, J W, Traynor, J R & Husbands, S M 2015, ' C7β-Methyl Analogues of the Orvinols : The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors ', Journal of Medicinal Chemistry, vol. 58, no. 10, pp. 4242-4249 . https://doi.org/10.1021/acs.jmedchem.5b00130
Cueva, J P, Roche, C, Ostovar, M, Kumar, V, Clark, M J, Hillhouse, T M, Lewis, J W, Traynor, J R & Husbands, S M 2015, ' C7β-Methyl Analogues of the Orvinols : The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors ', Journal of Medicinal Chemistry, vol. 58, no. 10, pp. 4242-4249 . https://doi.org/10.1021/acs.jmedchem.5b00130
Buprenorphine is a successful analgesic and treatment for opioid abuse, with both activities relying on its partial agonist activity at mu opioid receptors. However, there is substantial interest in its activities at the kappa opioid and nociceptin/o